Interventions & Treatments
Evidence-based analysis of longevity therapeutics.
The longevity industry is plagued by supplements with poor bioavailability and weak human data. We focus on pharmaceutical interventions with significant preclinical data (ITP trials) and ongoing human clinical trials.
Primary Therapeutics
Rapamycin (Sirolimus)
An mTOR inhibitor. The most robustly validated lifespan-extending pharmacological agent in mammalian models.
Read AnalysisMetformin
AMPK activator. Decades of epidemiological data, though recent data questions its utility in healthy, non-diabetic individuals.
Read AnalysisAcarbose
Alpha-glucosidase inhibitor. Blunts postprandial glucose spikes. Strong ITP data, especially in males.
Read AnalysisTherapeutic Plasma Exchange (TPE)
Dilutes systemic pro-aging factors (SASP). Currently undergoing clinical trials (e.g., AMBAR trial for Alzheimer's).
Read Analysis